Physician profile
Ambreen Fraser
NPI 1578557047
$4,950.22
in general payments reported to CMS, 2019-2025
12 companies · $881 in 2025
The $881 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $151 · 2021: $172 · 2022: $360 · 2023: $1,351 · 2024: $1,256 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,411 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,410.60 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,938.01 | 2020-2025 | Otezla, Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,027.53 | 2019-2025 | |
| Ucb, INC. | $623.57 | 2023-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $326.86 | 2023 | Tremfya |
| Janssen Scientific Affairs, LLC | $324.57 | 2021-2022 | |
| Abbvie INC. | $202.49 | 2019-2025 | |
| Lilly USA, LLC | $201.40 | 2023-2024 | Taltz, Olumiant |
| Mallinckrodt Hospital Products INC. | $119.70 | 2023 | Acthar |
| Aurinia Pharma U.S., INC. | $66.87 | 2024 | |
| Radius Health, INC. | $56.79 | 2024 | Tymlos |
| Genentech USA, INC. | $41.32 | 2019-2020 | |
| Cipher Pharmaceuticals US LLC | $21.11 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambreen Fraser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.